PL2812011T3 - Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo - Google Patents

Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo

Info

Publication number
PL2812011T3
PL2812011T3 PL13709575T PL13709575T PL2812011T3 PL 2812011 T3 PL2812011 T3 PL 2812011T3 PL 13709575 T PL13709575 T PL 13709575T PL 13709575 T PL13709575 T PL 13709575T PL 2812011 T3 PL2812011 T3 PL 2812011T3
Authority
PL
Poland
Prior art keywords
vivo
cell differentiation
hematopoietic cells
hematopoietic
cells
Prior art date
Application number
PL13709575T
Other languages
English (en)
Inventor
Jan Spanholtz
Harmen Dolstra
Original Assignee
Glycostem Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycostem Therapeutics B.V. filed Critical Glycostem Therapeutics B.V.
Publication of PL2812011T3 publication Critical patent/PL2812011T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13709575T 2012-02-08 2013-02-07 Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo PL2812011T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12154554 2012-02-08
EP13709575.8A EP2812011B1 (en) 2012-02-08 2013-02-07 Ex vivo nk cell differentiation from cd34+ hematopoietic cells
PCT/NL2013/050073 WO2013119118A1 (en) 2012-02-08 2013-02-07 Ex vivo nk cell differentiation from cd34+ hematopoietic cells

Publications (1)

Publication Number Publication Date
PL2812011T3 true PL2812011T3 (pl) 2020-06-29

Family

ID=47884461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13709575T PL2812011T3 (pl) 2012-02-08 2013-02-07 Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo

Country Status (7)

Country Link
US (3) US20150010583A1 (pl)
EP (1) EP2812011B1 (pl)
CA (1) CA2864283C (pl)
DK (1) DK2812011T3 (pl)
ES (1) ES2771248T3 (pl)
PL (1) PL2812011T3 (pl)
WO (1) WO2013119118A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016109661A1 (en) * 2014-12-31 2016-07-07 Anthrogenesis Corporation Natural killer cells and uses thereof
WO2017042393A1 (en) * 2015-09-11 2017-03-16 Emercell Sas Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease
WO2017046142A1 (en) * 2015-09-15 2017-03-23 Stichting Katholieke Universiteit IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
AU2016340005B2 (en) 2015-10-15 2023-09-07 Celularity Inc. Natural killer cells and ILC3 cells and uses thereof
MX2018013565A (es) * 2016-05-07 2019-08-21 Celularity Inc Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales.
IT201600121081A1 (it) * 2016-11-29 2018-05-29 Fond Ri Med Immunoterapia NK-mediata e usi di essa
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
MY197176A (en) 2018-02-01 2023-05-30 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
CN108315299A (zh) * 2018-02-13 2018-07-24 南京支云松生物科技有限公司 一种即用型异体nk细胞库网络储运应用系统
EP3802796A1 (en) * 2018-05-30 2021-04-14 Glycostem Therapeutics B.V. Car nk cells
WO2020124256A1 (en) * 2018-12-21 2020-06-25 Stemcell Technologies Canada Inc. Media and methods for differentiating natural killer cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
AU2019456283B2 (en) 2019-07-08 2023-06-08 Immunitybio, Inc. Mononuclear cell derived NK cells
US20220249567A1 (en) * 2019-07-22 2022-08-11 Glycostem Therapeutics B.V. Low density cell culture
JP2023504075A (ja) * 2019-11-28 2023-02-01 グリコステム セラピューティクス ベスローテン フェンノートシャップ Ｃａｒ－ｎｋ細胞を得る方法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CN113416700B (zh) * 2021-07-09 2023-04-11 天晴干细胞股份有限公司 一种高效的因子分泌型nk细胞扩增方法及其应用
KR102504039B1 (ko) * 2022-10-25 2023-03-02 오정훈 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297471A1 (en) * 2004-05-28 2009-12-03 Mayo Foundation For Medical Education And Research Methods For Autologous Stem Cell Transplantation
US7915043B2 (en) * 2005-03-18 2011-03-29 The Ohio State University Research Foundation CD34(+) cells and their methods of use
DK1941027T3 (da) * 2005-09-28 2014-10-13 Ipd Therapeutics B V Fremgangsmåder og midler til stamcelleforøgelse og efterfølgende generering og ekspansion af progenitorceller samt produktion af effektorceller som kliniske terapeutika
PL2142642T3 (pl) * 2007-03-27 2017-10-31 Ipd Therapeutics B V Sposoby i środki do proliferacji komórek macierzystych oraz następczego wytwarzania i ekspansji komórek progenitorowych, jak również wytwarzania komórek efektorowych jako leków klinicznych

Also Published As

Publication number Publication date
EP2812011A1 (en) 2014-12-17
WO2013119118A1 (en) 2013-08-15
EP2812011B1 (en) 2020-01-15
ES2771248T3 (es) 2020-07-06
US10822589B2 (en) 2020-11-03
CA2864283A1 (en) 2013-08-15
US20180044636A1 (en) 2018-02-15
US20150010583A1 (en) 2015-01-08
US20210054338A1 (en) 2021-02-25
DK2812011T3 (da) 2020-02-24
CA2864283C (en) 2020-11-03

Similar Documents

Publication Publication Date Title
PL2812011T3 (pl) Różnicowanie komórek NK z komórek hematopoetycznych CD34&lt;sup&gt;+&lt;/sup&gt; ex vivo
HRP20181515T1 (hr) Mezenhimne stromalne stanice i upotreba povezana s njima
HK1243729A1 (zh) 人胚胎幹細胞的分化
IL236679A0 (en) Preparations and methods for regulating car t cells
EP3699264C0 (en) THREE-DIMENSIONAL CELL CULTIVATION
EP2844738A4 (en) GENERATION OF NOVO OF PLURIPOTENT CELLS
EP2919313A4 (en) SOLID ELECTROLYTE
EP2709128A4 (en) ELECTROCHEMICAL CELL
SG11201503579RA (en) Cell culture med
SG11201500417PA (en) Cell culture
PT2626315E (pt) Tabuleiro alveolar
HK1199148A1 (en) Electrochemical cell
EP2831949A4 (en) SODIUM OXYGEN CELLS
EP2665811A4 (en) SOMATIC CELLS WITH POTENTIAL INNÉ OF PLURIPOTENCE
EP2860239A4 (en) VESSEL FOR BREEDING HUMAN ES CELLS
GB201118641D0 (en) Electrochemical cell
EP2924787A4 (en) SINGLE CELL OF FUEL CELL
EP2929586A4 (en) ELECTROCHEMICAL CELL ANAEROBIC ALUMINUM-WATER
EP2659574A4 (en) COOLING ARRANGEMENT USING AN ELECTROCHEMICAL CELL
EP2830138A4 (en) BIO FUEL CELL
IL239484A0 (en) Materials for omitting enterprise-tumor cells
EP2833462A4 (en) BATTERY WITH FIXED ELECTROLYTE
EP2742552A4 (de) Elektrochemische zellen
GB201220058D0 (en) Cell differentiation
GB201217016D0 (en) Parallel charging &amp; discharging of multiple batteries